Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Depreciation & Amortization (CF) (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Depreciation & Amortization (CF) data on record, last reported at $3.0 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) changed N/A year-over-year to $3.0 million; the TTM value through Dec 2025 reached $6.0 million, changed N/A, while the annual FY2025 figure was $10.0 million, 0.0% changed from the prior year.
  • Depreciation & Amortization (CF) reached $3.0 million in Q4 2025 per RCUS's latest filing, roughly flat from $3.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $3.0 million in Q4 2023 and bottomed at $800000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $1.8 million, with a median of $2.0 million recorded in 2022.
  • The widest YoY moves for Depreciation & Amortization (CF): up 200.0% in 2023, down 50.0% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.4 million in 2021, then decreased by 29.43% to $1.0 million in 2022, then soared by 200.0% to $3.0 million in 2023, then plummeted by 33.33% to $2.0 million in 2024, then surged by 50.0% to $3.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $3.0 million in Q4 2025, $3.0 million in Q1 2025, and $2.0 million in Q3 2024.